ClinicalTrials.gg
CompletedNCT00132678Updated Jul 29, 2013Results posted

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

A Phase 3 interventional study of Risperdal Consta and Placebo in Bipolar Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 52 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-07-29.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies testing risperidone in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Risperidone · Bipolar Disorder.

Enrollment
Largest of 29
559 · median 78
Started
2005
the only one that year
Phase 3
16 of 29
none open now
Registered
5th of 29
by date
Lead sponsor
10 of 29
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 29 studies testing risperidone in Bipolar Disorder, this one has the largest enrollment, is the only one that started in 2005, is one of 16 in phase 3, and was the 5th registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 29 studies testing risperidone in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing risperidone in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.

Read the detailed description

RISPERDAL CONSTA (risperidone long-acting injection) may provide substantial improvement, by reducing patient non-compliance, in the long-term treatment of bipolar I disorder. This is a randomized (patients are assigned different treatments based on chance), double-blind, (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage) placebo-controlled study to explore the safety and effectiveness of RISPERDAL CONSTA in the prevention of mood episodes in patients with bipolar 1 disorder. This study includes 5 periods: a screening period lasting up to 1 week; an open-label RISPERDAL (oral risperidone) treatment period lasting 3 weeks; an open-label RISPERDAL CONSTA stabilization period lasting 26 weeks; a double-blind period lasting up to 24 months; and an open-label extension with RISPERDAL CONSTA lasting 8 weeks. Efficacy will be assessed using the Young Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions - Severity (CGI-S) scale, Medical Outcomes Study Short Form 36 (SF-36), and the Personal and Social Performance (PSP) scale. Safety will be evaluated throughout the study and includes assessment of adverse events, clinical laboratory tests (including hematology, serum chemistry, blood glucose/lipid profile, prolactin, and urinalysis); electrocardiograms (ECGs), vital signs (pulse and blood pressure), physical examination, body mass index (BMI), and the Extrapyramidal Symptom Rating Scale (ESRS). Oral risperidone (flexible dosage) 1 to 6 mg/day for the first 3 weeks. Risperidone LAI i.m. injections (12.5mg, 25 mg, 37.5 mg, or 50 mg) given every 2 weeks for up to approximately 2.6 years (only 6 months for patients receiving placebo during DB-period)

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Mood episodes
  • Bipolar 1 disorder
  • Intramuscular Injectable
  • risperidone
  • safety and efficacy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or stable
  • Two or more bipolar mood episodes in the last 2 years excluding current episode
  • Negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • History of > than 4 mood episodes a year during the last two years
  • patients experiencing a depressive episode
  • History of antisocial or borderline personality illness
  • Has unstable or serious general medical illness
  • Has received medications disallowed by study criteria.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
559 participants (actual)

Study arms

  • Experimental
    001

    Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks

    Drug: Risperdal Consta

  • Placebo comparator
    002

    Placebo Matching placebo intramuscular (IM) injection every 2 weeks

    Drug: Placebo

Interventions

  • DrugRisperidoneStudies of RisperidoneRisperidone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks

  • DrugPlacebo

    Matching placebo intramuscular (IM) injection every 2 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had a Mood Relapse.

    Mood Relapse was defined as: The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \>12 or a CGI-S score \>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.

    Time frame: 24 months

Secondary outcomes

  1. Change in Young Mania Rating Scale (YMRS) Scores.

    Measure of mania; score range 0 to 60 (lower score = less severity)

    Time frame: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV

  2. Change in Montgomery-Åsberg Depression Rating Scale (MADRS)

    Measure of depression; score range 0 to 60 (lower score = less severity)

    Time frame: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV

07

Results

Posted Feb 27, 2009

Participant flow

A total of 559 (440 + 119) subjects received at least one dose of study drug. A total of 440 subjects (acute episode or stable on other antipsychotic) entered period II, 382 subjects completed and entered period III. An additional 119 subjects (stable on risperidone) entered period III directly. Overall 501 (382 + 119) subjects entered period III.

Period II (Open-Label Oral Risperidone)
Participant flow — Period II (Open-Label Oral Risperidone)
MilestoneRISPERDAL CONSTAPlaceboOpen-Label Oral Risperidone
Started00440
Completed00382
Not completed0058
Withdrew: Death001
Withdrew: Adverse event0013
Withdrew: Non responder006
Withdrew: Ineligible to continue trial007
Withdrew: Lost to follow-up0014
Withdrew: Withdrawal by subject0016
Withdrew: Physician decision001
Period III (Open-Label Stabilization)
Participant flow — Period III (Open-Label Stabilization)
MilestoneRISPERDAL CONSTAPlaceboOpen-Label Oral Risperidone
Started50100
Completed30300
Not completed19800
Withdrew: Death200
Withdrew: Adverse event1200
Withdrew: Non responder10700
Withdrew: Ineligible to continue trial500
Withdrew: Lost to follow-up1900
Withdrew: Withdrawal by subject4900
Withdrew: Subject non-compliant100
Withdrew: Physician decision100
Withdrew: Pregnancy200
Period IV (Double-Blind Treatment)
Participant flow — Period IV (Double-Blind Treatment)
MilestoneRISPERDAL CONSTAPlaceboOpen-Label Oral Risperidone
Started1541490
Completed1171090
Not completed37400
Withdrew: Adverse event110
Withdrew: Ineligible to continue the trial440
Withdrew: Lost to follow-up630
Withdrew: Withdrawal by subject14150
Withdrew: Physician decision10140
Withdrew: Subject non-compliant210
Withdrew: Pregnancy020

Outcome measures

PrimaryNumber of Participants Who Had a Mood Relapse.

Mood Relapse was defined as: The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \>12 or a CGI-S score \>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.

Time frame:
24 months
Reported as:
Number · Participants
Number of Participants Who Had a Mood Relapse.
ParticipantsRISPERDAL CONSTAPlacebo
Relapsed42 (173 to NA)76 (82 to NA)
Not Relapsed9859
Statistical analysis
  • RISPERDAL CONSTA vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.40 · 95% CI 0.27 to 0.59RISPERDAL CONSTA hazard in numerator, placebo hazard in denominator.
SecondaryChange in Young Mania Rating Scale (YMRS) Scores.

Measure of mania; score range 0 to 60 (lower score = less severity)

Time frame:
Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
Reported as:
Mean · units on a scale
Change in Young Mania Rating Scale (YMRS) Scores.
units on a scaleRISPERDAL CONSTAPlacebo
Change in Young Mania Rating Scale (YMRS) Scores.2.9 ± 7.349.1 ± 10.78
Statistical analysis
  • RISPERDAL CONSTA vs Placebo · ANCOVA · p = <0.001 · Mean difference (final values): -5.9 · 95% CI -8.08 to -3.79Change in RISPERDAL CONSTA arm minus change in placebo arm.
SecondaryChange in Montgomery-Åsberg Depression Rating Scale (MADRS)

Measure of depression; score range 0 to 60 (lower score = less severity)

Time frame:
Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
Reported as:
Mean · units on a scale
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
units on a scaleRISPERDAL CONSTAPlacebo
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)2.8 ± 6.664.9 ± 8.09
Statistical analysis
  • RISPERDAL CONSTA vs Placebo · ANCOVA · p = 0.020 · Mean difference (final values): -2.0 · 95% CI -3.75 to -0.32Change in RISPERDAL CONSTA arm minus change in placebo arm.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RISPERDAL CONSTA—13/154 (8.4%)28/154 (18.2%)
Placebo—25/149 (16.8%)24/149 (16.1%)
Open-Label Oral Risperidone—8/440 (1.8%)81/440 (18.4%)
Open Label RISPERDAL CONSTA—38/501 (7.6%)155/501 (30.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventRISPERDAL CONSTAPlaceboOpen-Label Oral RisperidoneOpen Label RISPERDAL CONSTA
ManiaPsychiatric disorders3/15410/1491/4402/501
Bipolar I disorderPsychiatric disorders3/1549/1492/44012/501
DepressionPsychiatric disorders5/1541/1490/44010/501
Psychotic disorderPsychiatric disorders0/1542/1490/4402/501
Bipolar disorderPsychiatric disorders0/1541/1491/4402/501
Major depressionPsychiatric disorders0/1541/1490/4400/501
Suicide attemptPsychiatric disorders0/1541/1491/4401/501
EpilepsyNervous system disorders0/1541/1490/4400/501
Diabetes mellitusMetabolism and nutrition disorders1/1540/1490/4400/501
Nasal polypsRespiratory, thoracic and mediastinal disorders1/1540/1490/4400/501
Most frequent other events
Most frequent other events
EventRISPERDAL CONSTAPlaceboOpen-Label Oral RisperidoneOpen Label RISPERDAL CONSTA
InsomniaPsychiatric disorders12/1549/14923/44066/501
HeadacheNervous system disorders11/15410/14933/44028/501
AgitationPsychiatric disorders2/1547/1495/44028/501
SommolenceNervous system disorders1/1541/14924/44013/501
Weight increasedInvestigations7/1541/1493/44027/501
AnxietyPsychiatric disorders4/1546/1496/44023/501

Baseline characteristics

Age Continuous
Age Continuous(years)RISPERDAL CONSTAPlaceboTotal
Mean39.1 ± 11.8139.2 ± 12.4039.2 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)RISPERDAL CONSTAPlaceboTotal
Female7968147
Male7581156
08

Study locations

52 sites
  • Little Rock, Arkansas, United States
  • La Mesa, California, United States
  • National City, California, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Hialeah, Florida, United States
  • Lake Charles, Louisiana, United States
  • Towson, Maryland, United States
  • Clementon, New Jersey, United States
  • Lyndhurst, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Desoto, Texas, United States
  • Richmond, Virginia, United States
  • Neunkirchen, Austria
  • Bangalore, India
  • Hyderabad, India
  • Manipal, India
  • Johor Bahru, Malaysia
  • Kota Bharu, Malaysia
  • Kuala Lumpur, Malaysia
  • Choroszcz N/A, Poland
  • Gdansk, Poland
  • Swiecie Poland, Poland
  • Tuszyn N/A, Poland
  • Lipetsk, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow Region, Russian Federation
  • Moscow Russia, Russian Federation
  • Nizny Novgorod, Russian Federation
  • Samara N/A, Russian Federation
  • Saratov N/A, Russian Federation
  • St Petersburg N/A, Russian Federation
  • St-Petersburg, Russian Federation
  • St-Petresburg, Russian Federation
  • Bratislava, Slovakia
  • Kosice, Slovakia
  • Rimavska Sobota, Slovakia
  • Barcelona, Spain
  • Madrid, Spain
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Tao-Yuan, Taiwan
  • Dnepropetrovsk, Ukraine
  • Glevakha, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Lvov, Ukraine
  • Odessa, Ukraine
  • Simferopol, Ukraine
  • Vinnitsa, Ukraine
09

References and documents

Publications

  • Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010 Jul 15;68(2):156-62. doi: 10.1016/j.biopsych.2010.01.015. Epub 2010 Mar 15. PubMed 20227682 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Aug 22, 2005
Start
Feb 2005
Primary completionActual
Oct 2007
CompletionActual
Dec 2007
Results first posted
Feb 27, 2009
Last update
Jul 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00132678
Responsible party
Sponsor
First posted
Aug 22, 2005
Start date
Feb 2005
Primary completion
Oct 2007
Completion
Dec 2007
Results posted
Feb 27, 2009
Last update
Jul 29, 2013

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion